• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Third Deal With Novartis Gets Emisphere $10M, Maybe More

Dec. 3, 2004
By Aaron Lorenzo

Third Deal With Novartis Gets Emisphere $10M, Maybe More

Dec. 3, 2004
By Aaron Lorenzo

Isotechnika Starts Phase III Psoriasis Study For ISA247

Dec. 3, 2004
By Aaron Lorenzo

FDA Committee United Against Marqibo's Accelerated Approval

Dec. 2, 2004
By Aaron Lorenzo

Clofarabine: Endorsed For Use In ALL, But Not AML

Dec. 2, 2004
By Aaron Lorenzo
SILVER SPRING, Md. - The FDA's Oncologic Drugs Advisory Committee split its vote regarding clofarabine, ILEX Oncology Inc.'s cancer product. (BioWorld Today)
Read More

Clofarabine: Endorsed For Use In ALL, But Not AML

Dec. 2, 2004
By Aaron Lorenzo
SILVER SPRING, Md. - The FDA's Oncologic Drugs Advisory Committee split its vote regarding clofarabine, ILEX Oncology Inc.'s cancer product. (BioWorld Today)
Read More

FDA Committee United Against Marqibo's Accelerated Approval

Dec. 2, 2004
By Aaron Lorenzo

Inex, Enzon, ILEX, Genzyme Part Of Today's ODAC Panel

Dec. 1, 2004
By Aaron Lorenzo
WASHINGTON - The FDA's oncology advisory committee is meeting today to form an opinion on two cancer drugs, clofarabine and Marqibo, and a review of the latter could prove dicey based on a briefing document made public by the agency Tuesday. (BioWorld Today)
Read More

Inex, Enzon, ILEX, Genzyme Part Of Today's ODAC Panel

Dec. 1, 2004
By Aaron Lorenzo
WASHINGTON - The FDA's oncology advisory committee is meeting today to form an opinion on two cancer drugs, clofarabine and Marqibo, and a review of the latter could prove dicey based on a briefing document made public by the agency Tuesday. (BioWorld Today)
Read More

BioMarin Files Aryplase BLA;EU Filing To Follow This Year

Nov. 30, 2004
By Aaron Lorenzo
BioMarin Pharmaceutical Inc. moved Aryplase (galsulfase) into the FDA's hands, filing for approval of the enzyme-replacement therapy for the treatment of mucopolysaccharidosis VI (MPS VI), an inherited and life-threatening disease for which no drug therapies are available. (BioWorld Today)
Read More
Previous 1 2 … 118 119 120 121 122 123 124 125 126 … 237 238 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe